Benefits
Memory in older adults with subjective cognitive decline
In a 12-month randomized placebo-controlled trial, 100 adults aged 60 to 90 with self-reported memory decline took 750 mg of extract a day (about 0.9 mg spermidine). The main memory measure, secondary outcomes and blood biomarkers did not differ from placebo. An earlier 3-month pilot in 30 people had suggested a memory gain that this larger trial did not confirm.
Brain blood flow and white matter structure on MRI
In an exploratory MRI analysis of 75 people from the 12-month memory trial, blood flow in one brain region (the precuneus) rose on the extract compared with placebo, and a white matter measure in the cingulate held steady while it fell on placebo. Brain volume, cortical thickness and white matter lesions did not differ, and the MRI changes were not linked to memory.
Cognitive test scores with spermidine-rich wheat germ bread rolls
In a 3-month double-blind study in 85 nursing home residents, most living with mild or moderate dementia, people ate a wheat germ roll (3.3 mg spermidine) or a wheat bran roll (1.9 mg) six days a week. Test scores rose in both groups, the groups were not compared directly, and no result met the authors' own corrected significance threshold. This tested a food, not an extract.
Effect on blood spermidine levels
In 30 older adults, 750 mg of extract a day (1.2 mg spermidine) for 3 months did not change whole-blood spermidine compared with placebo. In the bread roll study, serum spermidine rose in the group eating wheat germ rolls, which supplied more spermidine per day than typical extract capsules. Whether a roughly 1 mg serving changes tissue levels in people is unknown.
Standardized source of spermidine and spermine
EU novel food rules define the extract as made from non-fermented, non-sprouting wheat germ by an extraction aimed at polyamines, with 0.8 to 2.4 mg spermidine and 0.4 to 1.2 mg spermine per gram. The human trials used 750 mg of extract a day, giving 0.9 to 1.2 mg spermidine. The EU permits it in supplements for adults up to the equivalent of 6 mg spermidine a day.
Autophagy and lifespan in laboratory and animal studies
In mice, oral spermidine extended lifespan, increased autophagy in heart muscle and preserved heart relaxation in old age, and in aging flies and mice dietary spermidine supported brain mitochondrial function and memory. These are animal results with spermidine, not tests of the wheat germ extract in people, and no human trial has measured lifespan or the pace of aging.
Mechanism of action
Supplies spermidine for eIF5A hypusination
Spermidine is the raw material for hypusination, a chemical change to the protein translation factor eIF5A. In aging flies and mice, dietary spermidine raised hypusination, improved mitochondrial function in the brain and preserved memory. This pathway has been shown in animals and has not been measured in people taking wheat germ extract.
Autophagy-dependent effects in animal hearts
In old mice, spermidine increased autophagy and mitophagy in heart muscle, and its heart benefits disappeared in mice lacking the autophagy gene Atg5 in heart cells, which suggests autophagy is required. In salt-sensitive rats on a high-salt diet it lowered blood pressure. These findings come from animal models only.
Polyamines from the body, food and gut bacteria
The body makes its own polyamines and also takes them up from food and from the digestive tract. Tissue levels fall with age in some tissues, though they are maintained in healthy people in their nineties and older. Higher polyamine levels are associated with better health in observational data, which does not show that a supplement changes outcomes.
Clinical trials
Single-center, 12-month, randomized, double-blind, placebo-controlled phase 2b trial of 750 mg/day spermidine-rich wheat germ extract (about 0.9 mg spermidine and 0.5 mg spermine a day) supplied by The Longevity Labs (Schwarz et al. 2022, JAMA Netw Open)
100 adults aged 60 to 90 with subjective cognitive decline in Germany (51 extract, 49 placebo); 89 completed.
Mnemonic discrimination, the primary memory outcome, did not differ from placebo (between-group difference -0.03, 95% CI -0.11 to 0.05, P = .47), and secondary outcomes did not change. Exploratory signals for verbal memory and inflammation, and a slower Trail Making B time on the extract, would not survive correction for multiple testing. Adverse events were similar (58 vs 71 events), with musculoskeletal events in more people on the extract (11 vs 4). The maker funded development of the extract and several authors held equity in it.
Randomized, double-blind, placebo-controlled phase 2a pilot of 750 mg/day wheat germ extract giving 1.2 mg spermidine a day for 3 months (Wirth et al. 2018, Cortex)
30 cognitively intact adults aged 60 to 80 with subjective cognitive decline.
Memory performance favored the extract by effect size (contrast .17, 95% CI -.01 to .35; Cohen's d .77), an imprecise estimate whose interval included no difference. The authors called for a larger trial; the 12-month SmartAge trial that followed found no memory benefit. The safety report from this same trial lists a financial interest in the maker for several authors.
Randomized, double-blind, placebo-controlled phase 2 safety analysis of 3 capsules a day (750 mg extract; 1.2 mg spermidine, 0.6 mg spermine, 0.2 mg putrescine) for 3 months, with a 28-day oral toxicity study in mice (Schwarz et al. 2018, Aging (Albany NY))
30 adults aged 60 to 80 with subjective cognitive decline (28 completed); people with a known wheat germ or gluten allergy were excluded.
There were no between-group differences in vital signs, weight, blood chemistry or blood counts, and whole-blood spermidine did not change (8.5 to 8.3 nmol/ml on the extract). There was one serious adverse event per group, neither judged related. Compliance was 98%. Four authors had a financial interest in the maker, The Longevity Labs.
Exploratory secondary MRI analysis of the 12-month randomized, double-blind, placebo-controlled SmartAge trial of 0.9 mg/day spermidine from wheat germ extract (Schwarz et al. 2026, Aging Dis)
75 adults aged 60 to 90 with subjective cognitive decline.
Precuneus blood flow rose versus placebo (difference 4.9 ml/100 g/min, 95% CI 1.0 to 8.9, P = .015), and cingulate white matter fractional anisotropy stayed stable while it fell on placebo (P = .029). Brain volume, cortical thickness and white matter lesions did not differ, and the MRI changes were not associated with memory changes. The authors call the findings preliminary and in need of independent confirmation.
Randomized, double-blind, multicenter two-group trial comparing a wheat germ roll (3.3 mg spermidine per roll) with a wheat bran roll (1.9 mg) eaten at breakfast six days a week, with no placebo group (Pekar et al. 2021, Wien Klin Wochenschr)
85 analyzed of 92 enrolled residents of six nursing homes in Styria, Austria, mean age 83; most had mild or moderate dementia.
CERAD total scores rose in both groups (6.25 and 4.00 points) with no direct between-group comparison; in the mild dementia subgroup, MMSE rose 2.23 points on the wheat germ roll (P = .026). None of these met the authors' Bonferroni threshold of P < .0167. Serum spermidine rose only with the wheat germ roll. The study was investigator funded and tested a food, not an extract supplement.